La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Softchoice Corp Ordinary Shares a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Softchoice Corp Ordinary Shares..

Softchoice Corp Ordinary Shares (OTC:SFTCF) Azioni, Catena delle Opzioni

Softchoice Corp Ordinary Shares

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="3" rowspan="1">
BAXTER INTERNATIONAL INC.
Reconciliation of Non-GAAP Financial Measures
Projected Third Quarter and Full Year 2025 U.S. GAAP Sales Growth to Projected Operational Sales Growth and Projected Third Quarter and Full Year 2025 Adjusted Earnings Per Share
(unaudited)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Sales Growth Guidance</td>
<td colspan="1" rowspan="1">Q3 2025&#x2A;</td>
<td colspan="1" rowspan="1">FY 2025&#x2A;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Sales growth - U.S. GAAP</td>
<td colspan="1" rowspan="1">6% - 7%</td>
<td colspan="1" rowspan="1">6% - 7%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Kidney Care MSA</td>
<td colspan="1" rowspan="1">(~300 bps)</td>
<td colspan="1" rowspan="1">(~300 bps)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Exit of IV Solutions in China</td>
<td colspan="1" rowspan="1">~70 bps</td>
<td colspan="1" rowspan="1">~50 bps</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Foreign Exchange</td>
<td colspan="1" rowspan="1">(~100 bps)</td>
<td colspan="1" rowspan="1">(~50 bps)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operational sales growth</td>
<td colspan="1" rowspan="1">3% - 4%</td>
<td colspan="1" rowspan="1">3% - 4%</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Adjusted Earnings Per Share Guidance</td>
<td colspan="1" rowspan="1">Q3 2025</td>
<td colspan="1" rowspan="1">FY 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted diluted EPS</td>
<td colspan="1" rowspan="1">$0.58 - $0.62</td>
<td colspan="1" rowspan="1">$2.42 - $2.52</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&#x2A;Totals may not foot due to rounding</td>
</tr>
</tbody>
</table>
</figure>

News

Guidance

Baxter Intl Sees Q3 Sales $2.860B-$2.887B vs $2.911B Est

Banco De Chile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCH#NYSE">BCH</a>) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.63 by 3.17 percent. This is a 4.41 percent decrease over earnings of $0.68 per share from the same period last year. The company reported quarterly sales of $818.700 million which missed the analyst consensus estimate of $828.930 million by 1.23 percent. This is a 0.09 percent increase over sales of $818.000 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Banco De Chile Q2 EPS $0.65 Beats $0.63 Estimate, Sales $818.700M Miss $828.930M Estimate

Obsidian Energy Launches Offer To Purchase Up To $48.4M Of 11.95% Senior Unsecured Notes Due 2027 At $1,030 Per $1,000 Face Value

Osisko Development To Raise Up To $195M Through Brokered And Non-Brokered Offerings At $2.05 Per Unit

Baird analyst Michael Ha downgrades UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) from Neutral to Underperform and lowers the price target from $312 to $198.

Downgrades

Price Target

Analyst Ratings

Baird Downgrades UnitedHealth Group to Underperform, Lowers Price Target to $198

Rosenblatt analyst Kevin Cassidy maintains ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Buy and maintains $180 price target.

Rosenblatt Maintains Buy on ARM Holdings, Maintains $180 Price Target

Baxter Intl Sees Q3 Adj EPS $0.58-$0.62 vs $0.65 Est

QuantaSing To Fully Acquire Letsvan Via Share Deal, Issuing 18.2M Class A Shares; Appoints Founder Zack Zhan To Board Effective August 1

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) with a Buy and raises the price target from $50 to $65.

IONS

HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $65

Baxter Intl Lowers FY2025 Adj EPS Guidance from $2.47-$2.55 to $2.42-$2.52 vs $2.52 Est; Lowers FY2025 Sales Guidance from $11.381B-$11.487B to $11.274B-$11.380B vs $11.378B Est

Electra Battery Materials Corporation (NASDAQ:<a href="https://www.benzinga.com/stock/ELBM#NASDAQ">ELBM</a>, TSXV:<a href="https://www.benzinga.com/stock/ELBM#TSXV">ELBM</a>) ("Electra" or the "Company") announces the start of metallurgical testing on cobalt feedstock from two strategic North American sources: the historic Cobalt Camp in Ontario and home to Electra's refinery, and the Company's Iron Creek cobalt and copper project in Idaho.
The objective of this initiative is to strengthen and diversify Electra's cobalt refinery feedstock pipeline by integrating domestic sources alongside existing global supply partners. This program supports the development of a robust, flexible, and resilient North American critical minerals supply chain while maintaining strategic relationships with partners such as Glencore and ERG. These domestic sources are intended to supplement Electra's existing international feedstock agreements, enhancing long-term security and operational flexibility.
Preliminary results from Electra's North American feedstock program are expected by the end of 2025 and will inform potential front-end flowsheet modifications, such as the proposed addition of a pressure oxidation (POX) circuit to enable processing of a broader range of complex concentrates. Electra's in-house laboratory is in the process of installing equipment required to evaluate these new feedstocks. Backed by a highly experienced technical team, the lab will conduct bench-scale testing and analytical work to validate and refine proposed flowsheet enhancements to the leach circuit designed to process North American materials at the Company's hydrometallurgical refinery, including arsenic-bearing polymetallic sulfide materials.

ELBM

Electra Begins Testing US and Canadian Cobalt to Boost North American Battery Supply Chain

XRTX

XORTX Announces $114,500 Private Placement To Support Gout Programs; Units Priced At $0.73 With 60-Month Warrants Exercisable At $1.20

<ul>
<li>Visa cardholders will score exclusive first access for a chance to purchase tickets to the world's biggest tournament</li>
<li>Visa plans to help local businesses in Canada, Mexico and the United States get ready to maximize economic opportunity</li>
</ul>

Visa And FIFA Team Up To Offer Global Cardholders Priority Access To World Cup 26 Tickets With Exclusive Presale

Baird analyst Peter Arment downgrades Albany International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) from Outperform to Neutral and maintains the price target from $79 to $79.

Baird Downgrades Albany International to Neutral, Maintains Price Target to $79

MRNA

Moderna To Cut Workforce By ~10%

Huntington Ingalls Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) affirms FY2025 sales outlook from $11.800 billion-$12.200 billion to $11.800 billion-$12.200 billion vs $11.908 billion estimate.

Huntington Ingalls Indus Affirms FY2025 Sales Guidance of $11.800B-$12.200B vs $11.908B Est

Second Quarter 2025&nbsp;HIGHLIGHTS
Corporate&nbsp;Highlights
<ul>
<li>Safety:&nbsp;The Nevada Mining Association&nbsp;("NVMA") awarded Hycroft the 2025 first place NVMA Operator Safety&nbsp;Award for small surface mines.&nbsp;Hycroft has maintained a 0.00 TRIFR for more than two and a half years, operating over 1.3-million-man hours without a Lost Time Incident. &nbsp;</li>
<li>Environmental:&nbsp; Through June 30, 2025, Hycroft maintained an impeccable environmental record and was recognized as stewards of successful reclamation. &nbsp;</li>
<li>Balance&nbsp;Sheet:&nbsp;The&nbsp;Company&nbsp;ended&nbsp;the&nbsp;second quarter&nbsp;with&nbsp;unrestricted cash of $68.8&nbsp;million, restricted cash of $30.0 million&nbsp;and total debt of $131.0 million.</li>
</ul>

Hycroft Mining Holding Corporation - Class A Common Stock

HYMC

Hycroft Mining Holding Ended Q2 With $98.8M Cash

Stagwell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>) affirms FY2025 Adj EPS guidance from $0.75-$0.88 to $0.75-$0.88 vs $0.78 analyst estimate. Affirms FY2025 sales outlook from $3.069 billion to $3.069 billion vs $2.921 billion estimate.

STGW

Stagwell Affirms FY2025 Adj EPS Guidance of $0.75-$0.88 vs $0.78 Est; Affirms FY2025 Sales Guidance of $3.069B vs $2.921B Est

Biotech

Health Care

Management

General

BCRX

BioCryst Pharmaceuticals' President And CEO, Jon Stonehouse Will Retire On December 31, The Company Has Appointed Charlie Gayer, Currently The Company's Chief Commercial Officer, As The Next President, Effective August 1, And Next CEO, Effective January 1, 2026

Rosenblatt analyst Kevin Cassidy maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Buy and raises the price target from $53 to $90.

Comments

Softchoice Corp Ordinary Shares

Softchoice Corp Ordinary Shares (SFTCF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO